Zervimesine
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference
Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program